Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
EndoSphere
company
About
Endosphere develops non-invasive medical devices used for treating metabolic diseases.
- 1 - 10
Highlights
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1M
- Industries
- Health Care,Life Science,Medical Device
- Founded date
- Jan 1, 2006
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Endosphere is a developer of the novel endo-metabolic device category that provides non-invasive endoscopic therapies for gastrointestinal (GI) disorders and metabolic diseases including obesity, non-alcoholic fatty liver disease, type 2 diabetes, and drug delivery. It treats obesity using the body's natural physiology that enables patients to safely and effectively lose weight without the need for surgery or medications.Endosphere was founded in 2006 and is headquartered in Columbus, Ohio.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$1M
EndoSphere has raised a total of
$1M
in funding over 2 rounds. Their latest funding was raised on
Apr 19, 2012 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 19, 2012 | Grant | $1M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
EndoSphere is funded by 1 investors.
Ohio Department of Development
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
